223 related articles for article (PubMed ID: 31384471)
1. Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2.
Oranje P; Gouka R; Burggraaff L; Vermeer M; Chalet C; Duchateau G; van der Pijl P; Geldof M; de Roo N; Clauwaert F; Vanpaeschen T; Nicolaï J; de Bruyn T; Annaert P; IJzerman AP; van Westen GJP
Pharmacol Res Perspect; 2019 Aug; 7(4):e00504. PubMed ID: 31384471
[TBL] [Abstract][Full Text] [Related]
2. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
Chang HC; Yang SF; Huang CC; Lin TS; Liang PH; Lin CJ; Hsu LC
Mol Biosyst; 2013 Aug; 9(8):2010-20. PubMed ID: 23657801
[TBL] [Abstract][Full Text] [Related]
4. Development of SGLT1 and SGLT2 inhibitors.
Rieg T; Vallon V
Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
[TBL] [Abstract][Full Text] [Related]
5. N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors.
Chu KF; Yao CH; Song JS; Chen CT; Yeh TK; Hsieh TC; Huang CY; Wang MH; Wu SH; Chang WE; Chao YS; Lee JC
Bioorg Med Chem; 2016 May; 24(10):2242-50. PubMed ID: 27075813
[TBL] [Abstract][Full Text] [Related]
6. Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors.
Blaschek W
Planta Med; 2017 Aug; 83(12-13):985-993. PubMed ID: 28395363
[TBL] [Abstract][Full Text] [Related]
7. The Na
Koepsell H
Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781
[TBL] [Abstract][Full Text] [Related]
8. A selectivity study of sodium-dependent glucose cotransporter 2/sodium-dependent glucose cotransporter 1 inhibitors by molecular modeling.
Xu J; Yuan H; Ran T; Zhang Y; Liu H; Lu S; Xiong X; Xu A; Jiang Y; Lu T; Chen Y
J Mol Recognit; 2015 Aug; 28(8):467-79. PubMed ID: 25753971
[TBL] [Abstract][Full Text] [Related]
9. Development of a cell-based nonradioactive glucose uptake assay system for SGLT1 and SGLT2.
Kanwal A; Singh SP; Grover P; Banerjee SK
Anal Biochem; 2012 Oct; 429(1):70-5. PubMed ID: 22796500
[TBL] [Abstract][Full Text] [Related]
10. SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study.
Lv Y; Cheng X; Dong Q
Cardiovasc Diabetol; 2024 May; 23(1):157. PubMed ID: 38715111
[TBL] [Abstract][Full Text] [Related]
11. A 96-well automated method to study inhibitors of human sodium-dependent D-glucose transport.
Castaneda F; Kinne RK
Mol Cell Biochem; 2005 Dec; 280(1-2):91-8. PubMed ID: 16311909
[TBL] [Abstract][Full Text] [Related]
12. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
13. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
14. 5,5-Difluoro- and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors.
Xu G; Du F; Kuo GH; Xu JZ; Liang Y; Demarest K; Gaul MD
Bioorg Med Chem Lett; 2020 Sep; 30(17):127387. PubMed ID: 32738984
[TBL] [Abstract][Full Text] [Related]
15. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
16. Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.
Cai W; Jiang L; Xie Y; Liu Y; Liu W; Zhao G
Med Chem; 2015; 11(4):317-28. PubMed ID: 25557661
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Yakovleva T; Sokolov V; Chu L; Tang W; Greasley PJ; Peilot Sjögren H; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
Diabetes Obes Metab; 2019 Dec; 21(12):2684-2693. PubMed ID: 31423699
[TBL] [Abstract][Full Text] [Related]
18. Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs.
Mashraqi MM; Chaturvedi N; Alam Q; Alshamrani S; Bahnass MM; Ahmad K; Alqosaibi AI; Alnamshan MM; Ahmad SS; Beg MMA; Mishra A; Shaikh S; Rizvi SMD
Molecules; 2021 Jan; 26(3):. PubMed ID: 33499241
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.
Solini A; Rossi C; Mazzanti CM; Proietti A; Koepsell H; Ferrannini E
Diabetes Obes Metab; 2017 Sep; 19(9):1289-1294. PubMed ID: 28419670
[TBL] [Abstract][Full Text] [Related]
20. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
